IRCT20241215064059N1 IRCT 2025-01-04 Tehran University of Medical Sciences Investigating the effect of drug treatment protocol in cerebral Evaluating the effect of the comprehensive drug protocol for spasticity in cerebral palsy patients in terms of gait analysis, clinical examination, radiographic changes, complications and quality of life. 2025-01-17 anticipated 31 Complete https://irct.ir/trial/80758 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 spastic cerebral palsy. In this study, the effectiveness of drug therapy in cerebral palsy patients who were included in the study according to the inclusion and exclusion criteria will be examined according to the following protocol. Selection of treatment type: - Treatment of generalized spasticity 1- First line: Baclofen (maximum dose 2.5 mg/kg/day), Tizanidine (4 mg/kg/day) 2- Second line: Dantrolene (12 mg/kg/day), Diazepam (0.01-0.3 mg/kg/day) 3- Third line (intraspinal baclofen (50 micrograms on the first day, 75 micrograms on the second day, 100 micrograms on the third day) - Treatment with local aim (both in generalized and local spasticity) 1- Botulinum toxin {Dysport, Masport, Dyston} (upper, lower limbs): 30 U/kg Treatment based on specific conditions - Pain (botulinum toxin, Tizanidine, oral baclofen, Diazepam, Dantrolene, intraspinal baclofen) - Disorder Sleep (tizanidine, oral baclofen, diazepam) - mixed type with dystonia (botulinum toxin, oral baclofen, diazepam) - post-operative pain due to spasm (diazepam, botulinum toxin, oral baclofen) - seizures (tizanidine, diazepam * Caution regarding the use of baclofen, dantrolene and intrathecal baclofen; After giving the above drugs to each of the patients with the specified dosage in the first three visits, 3 and 6 months later, the patients are examined with examination and radiology and the results of the study are recorded. If the drug results improve, it is continued, and if the results are not favorable, the second line is started.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information available.